SSRI Dosing for OCD: Beyond FDA Guidelines
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA G...
Radio and PodcastLive Radio & PodcastsHealth
Psychopharmacology and Psychiatry Updates
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and...
Episodes
20 of 131 episodesTrazodone for Insomnia and Comorbid Depression
In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, exami...
Antipsychotics, Prolactin, and Sexual Side Effects
In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop trea...
EMERGENT-5: Cobenfy and Treatment Durability
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability...
Antipsychotics and Weight Gain
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications ca...
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Ve...
AUD Medications and Hepatic Safety
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical a...
GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a...
Gabapentin, Topiramate & Baclofen in AUD
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use diso...
Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are...
Disulfiram Unpacked: Efficacy, Risks, and Liver Safety
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino br...
GLP-1s and Lithium: What Clinicians Need to Know
In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the w...
Naltrexone for Alcohol Use Disorder: What You Should Know
In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safe...
The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life
In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when...
Difficult-to-Treat Depression: First, Second, and Third-Line Strategies
In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting b...
Is High-Dose Olanzapine A Clozapine Alternative?
In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients wit...
CANMAT Guidelines: Herbs, Supplements, and Depression
In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John...
Xylazine in the ED: Managing Toxicity
In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what cl...
Choosing the First Step in Depression Treatment: A CANMAT Guide
In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, p...
After Delirium Clears: When to Deprescribe?
In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could...